Clinical Trial Update: Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma [Phase 1]

View source ↗

Summary

Phase 1 safety study of Tarceva (erlotinib) in children with refractory/relapsed malignant brain tumors and brainstem glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Brainstem Glioma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Malignant Brain Tumor, Brain Stem Glioma, | Phase 1 | Status: COMPLETED